Suspension of substitute Medicare Benefits Schedule (MBS) items for nuclear medicine

Page last updated: 02 March 2021

Suspension of substitute Medicare Benefits Schedule (MBS) items for nuclear medicine

Date of change: 28 February 2021

From 28 February 2021, the eleven substitute nuclear medicine items (61311, 61332, 61365, 61377, 61380, 61418, 61422, 61333, 61336, 61337 and 61341) that became available from 1 December 2020 will cease following the full resumption of nuclear medicine production at the Lucas Heights facility of the Australian Nuclear Science and Technology Organisation (ANSTO). With supplies of technetium at normal levels, requestors and providers of diagnostic imaging items must revert to using the technetium-based nuclear medicine imaging items set out in the Health Insurance (Diagnostic Imaging Services Table) Regulation (No.2) 2020. Medicare rebates will no longer be available for any substitute item, including the substitute attenuation correction item (61344), performed after 28 February 2021.

PDF version Changes to nuclear medicine
Word version Changes to nuclear medicine

In this section